These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8708409)

  • 41. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
    Remington KM; Zhu YQ; Phillips TR; North TW
    J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interactions of the HIV-1 reverse transcriptase 'AZT-resistant' mutant with substrates and AZT-TP.
    Pokholok DK; Gudima SO; Yesipov DS; Dobrynin VN; Rechinsky VO; Kochetkov SN
    FEBS Lett; 1993 Jul; 325(3):237-41. PubMed ID: 7686510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.
    Richman DD
    Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.
    Imamichi T; Berg SC; Imamichi H; Lopez JC; Metcalf JA; Falloon J; Lane HC
    J Virol; 2000 Dec; 74(23):10958-64. PubMed ID: 11069990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
    Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
    Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.
    Nikolenko GN; Delviks-Frankenberry KA; Palmer S; Maldarelli F; Fivash MJ; Coffin JM; Pathak VK
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):317-22. PubMed ID: 17179211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
    Boyer PL; Das K; Arnold E; Hughes SH
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7184-96. PubMed ID: 26324274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Apr; 76(7):3248-56. PubMed ID: 11884549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
    J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.
    Albert J; Wahlberg J; Lundeberg J; Cox S; Sandström E; Wahren B; Uhlén M
    J Virol; 1992 Sep; 66(9):5627-30. PubMed ID: 1380098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Larder BA
    J Gen Virol; 1994 May; 75 ( Pt 5)():951-7. PubMed ID: 7513745
    [No Abstract]   [Full Text] [Related]  

  • 55. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients.
    Calderón EJ; Torres Y; Medrano FJ; Luque F; Larder B; Rey C; Sánchez-Quijano A; Lissen E; Leal M
    Eur J Clin Microbiol Infect Dis; 1995 Jun; 14(6):512-9. PubMed ID: 7588824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.
    Delviks-Frankenberry KA; Nikolenko GN; Barr R; Pathak VK
    J Virol; 2007 Jul; 81(13):6837-45. PubMed ID: 17428874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
    Rusconi S; De Pasquale MP; Milazzo L; Moscatelli G; Bulgheroni E; Citterio P; d'Arminio-Monforte A; Moroni M; Galli M
    Antivir Ther; 1997 Jan; 2(1):39-46. PubMed ID: 11322265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.